Skip to main content
Delta-Fly Pharma, Inc. logo

Delta-Fly Pharma, Inc. — Investor Relations & Filings

Ticker · 4598 ISIN · JP3549370009 T Professional, scientific and technical activities
Open in API
Filings indexed 63 across all filing types
Latest filing 2022-02-14 Interim / Quarterly Rep…
Country JP Japan
Listing T 4598

About Delta-Fly Pharma, Inc.

https://www.delta-flypharma.co.jp/en/

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer drugs. The company's core strategy is its proprietary "Module Drug Development" concept, an approach that combines existing pharmaceutical components to create novel therapeutic agents. This methodology aims to develop effective cancer treatments with significantly reduced side effects and at reasonable prices, thereby improving the quality of life for patients. The company's pipeline includes several drug candidates for various cancers, with some, such as DFP-10917 for refractory/relapsed acute myeloid leukemia, advancing to late-stage clinical trials. Delta-Fly Pharma focuses on creating gentle yet potent therapies, including nucleoside analogs and RNA therapeutics.

Recent filings

Filing Released Lang Actions
四半期報告書－第12期第3四半期(令和3年10月1日－令和3年12月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Delta-Fly Pharma, Inc., covering the third quarter of the fiscal year ending 2022. It includes detailed financial statements (balance sheet, income statement), notes to financial statements, and management analysis, which are characteristic of an Interim/Quarterly Report (IR). It is not a mere announcement (RPA) as it contains the full financial data and disclosures required by the Financial Instruments and Exchange Act of Japan. 9M 2022
2022-02-14 Japanese
四半期報告書－第12期第2四半期(令和3年7月1日－令和3年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Delta-Fly Pharma, Inc. covering the second quarter of the 12th fiscal period (April 1, 2021, to September 30, 2021). It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement, as well as management analysis and notes. This fits the definition of an Interim/Quarterly Report (IR). H1 2022
2021-11-11 Japanese
四半期報告書－第12期第1四半期(令和3年4月1日－令和3年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Delta-Fly Pharma, Inc. covering the first quarter of the 12th fiscal year (April 1, 2021, to June 30, 2021). It contains detailed financial statements (balance sheet, income statement), management analysis, and notes to the financial statements, which confirms it is a comprehensive interim financial report rather than an announcement or a summary. Therefore, it is classified as an Interim / Quarterly Report (IR). Q1 2022
2021-08-13 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, specifically related to an amendment of a Securities Report (訂正有価証券報告書). In the Japanese regulatory context, this is a formal filing submitted to the Financial Bureau to confirm the accuracy of financial disclosures. Since it does not fit into specific categories like 10-K or IR (as it is a confirmation of an amendment rather than the report itself) and is a formal regulatory submission, it falls under the RNS (Regulatory Filings) category. FY 2021
2021-07-06 Japanese
訂正有価証券報告書－第11期(令和2年4月1日－令和3年3月31日)
Annual Report Classification · 100% confidence The document is a 'Correction Report' (訂正有価証券報告書) for an Annual Securities Report (有価証券報告書). It contains detailed financial data, management indicators, and business descriptions for Delta-Fly Pharma, Inc. for the fiscal year ending March 31, 2021. While it is a correction, it functions as the primary annual financial disclosure document (10-K equivalent in the Japanese market). FY 2021
2021-07-06 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1, in Japan. This is a mandatory document accompanying the Annual Securities Report (Yukashoken Hokokusho) where the CEO confirms the accuracy of the report's contents. Since it is a regulatory filing confirming the validity of financial reporting and does not fit into specific categories like 10-K or IR, it is classified as a Regulatory Filing (RNS). FY 2021
2021-06-30 Japanese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.